



## Nanoparticle Delivery to Tumors: Challenges and Advances

Guest Editors:

**Dr. Sangeeta Ray**

Department of Radiology, Johns  
Hopkins University School of  
Medicine, Baltimore, MD 21205,  
USA

**Dr. Ethel J. Ngen**

Department of Radiology, Johns  
Hopkins University School of  
Medicine, Baltimore, MD 21205,  
USA

Deadline for manuscript  
submissions:

**closed (31 July 2023)**

### Message from the Guest Editors

Dear Colleagues,

Nanoparticles have emerged as versatile drug delivery vehicles for applications in oncology and other pathologies. However, although several types of nanoparticles have been developed, their effective delivery to tumors is still a major challenge, especially nanoparticles  $\geq 100$  nm in diameter. Enhanced vascular permeability in tumors has been shown to play an essential role in the delivery of nanoparticles of this diameter range to tumors, through the enhanced permeability and retention (EPR) effect. Furthermore, the poor clinical performance of some nanoparticles has been partially attributed to variabilities in the vascular permeability within tumors and within different patient populations. Consequently, tumor-priming strategies designed specifically to enhance tumor vascular permeability and subsequently increase the delivery of nanoparticles to tumors are currently being explored. In this Special Issue, we shall cover some of the challenges associated with delivering nanoparticles to tumors, and some advances that have been made to increase the delivery efficiency of nanoparticles to tumors.

Dr. Sangeeta Ray

Dr. Ethel J. Ngen

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Patrick J. Sinko**

Department of Pharmaceutics,  
Ernest Mario School of  
Pharmacy, Rutgers University,  
Piscataway, NJ 08854, USA

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceutics* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
X@MDPIpharma